Europska Unija - malteški - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europska Unija - malteški - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - lewkimja, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Europska Unija - malteški - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - it-terapija tal-qalb - kura sintomatika ta kronika stabbli, anġina pectorisivabradine huwa indikat għat-trattament tas-sintomi ta ' angina pectoris kronika stabbli fil-mard tal-arterji koronarji adulti b'ritmu sinusali normali u rata tal-qalb ≥ 70 bpm. ivabradine huwa indikat:fl-adulti li ma jistgħux jittolleraw jew bil-kontra-indikazzjoni għall-użu tal-beta-blockersor flimkien ma ' beta blockers f'pazjenti mhux ikkontrollati adegwatament bil-aħjar beta-blocker-doża. it-trattament tal-qalb kroniku failureivabradine huwa indikat f'insuffiċjenza kronika tal-qalb nyha ii-iv tal-klassi b'disfunzjoni sistolika, fil-pazjenti fl-sinus ritmiku u li d-rata tal-qalb huwa ≥ 75 bpm, f'kombinazzjoni ma ' terapija standard, inklużi l-beta-blockers jew meta beta-blockers huwa kontra-indikati jew mhux ittollerati.

Europska Unija - malteški - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - epatite Ċ, kronika - antivirali għal użu sistemiku - daklinza huwa indikat flimkien ma 'prodotti mediċinali oħra għall-kura ta' infezzjoni kronika tal-virus tal-epatite Ċ (hcv) fl-adulti (ara sezzjonijiet 4. 2, 4. 4 u 5. għall-ġenotip hcv-attività speċifika, ara sezzjonijiet 4. 4 u 5.

Europska Unija - malteški - EMA (European Medicines Agency)

elanco gmbh - benazepril hydrochloride, pimobendan - inibituri ace, kombinazzjonijiet - klieb - għall-kura ta 'insuffiċjenza tal-qalb konġestiva minħabba insuffiċjenza ta' valv atrijoventrikulari jew kardjomijopatija dilwita fil-klieb.

Europska Unija - malteški - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - terapija kardijaka - trattament sintomatiċi tal pectoris anġina stabbli kronika ivabradine huwa indikat għall-trattament sintomatiċi tal kronika anġina pectoris stabbli fil-coronary artery marda adulti b ' ritmu sinus normali u r-rata tal-qalb ≥ 70 bpm. ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. trattament ta ' nuqqas kroniku tal-qalb ivabradine huwa indikat fil-falliment tal-qalb kroniku nyha ii sa iv klassi ma ovarja skjaramenti, fil-pazjenti fl-sinus ritmu u li r-rata tal-qalb huwa ≥ 75 bpm, flimkien ma ' terapija standard inkluża terapija beta-blocker jew meta terapija beta-blocker hija contraindicated jew mhux tollerat.

Europska Unija - malteški - EMA (European Medicines Agency)

helsinn birex pharmaceuticals ltd. - palonosetron hydrochloride - vomiting; cancer - anti-emetiċi u anti-nawżjanti, , serotonin (5ht3) antagonisti - aloxi hu indikat fl-adulti għall -: il-prevenzjoni ta ' dardir u rimettar assoċjati ma'kimoterapija tal-kanċer ferm emetoġenika,il-prevenzjoni ta'nawseja u rimettar assoċjati ma'kimoterapija tal-kanċer moderatament emetoġenika. aloxi hu indikat f'pazjenti pedjatriċi 1 xahar ta'l-età u akbar għal:prevenzjoni ta ' dardir u rimettar assoċjati ma'kimoterapija tal-kanċer ferm emetoġenika u għall-prevenzjoni ta'nawseja u rimettar assoċjati ma'kimoterapija tal-kanċer moderatament emetoġenika.

Europska Unija - malteški - EMA (European Medicines Agency)

recordati rare diseases - mercaptamine hydrochloride - Ċistinosi - oftalmoloġiċi - cystadrops huwa indikat għat-trattament tad-depożiti tal-kristalli taċ-ċistini tal-kornea f'adulti u tfal minn sentejn b'ċistinosi.

Europska Unija - malteški - EMA (European Medicines Agency)

janssen-cilag international n.v.    - rilpivirine hydrochloride - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - edurant, f ' għaqda mal-oħrajn prodotti mediċinali antiretroviral, huwa indikat għall-trattament tal-virus ta ' immunodefiċjenza umani tat-tip 1 (hiv‑1) infezzjoni fil-pazjenti treatment‑naïve antiretroviral 12-il sena ta ' l-età u l-aktar antiki mal-≤ tagħbija virali 100,000 hiv‑1 rna kopji/ml. bħala ma ' prodotti mediċinali antiretrovirali oħra, l-ittestjar tar-reżistenza ġenotipika għandhom jiggwidaw l-użu tal-edurant.

Europska Unija - malteški - EMA (European Medicines Agency)

virbac s.a. - clomipramine hydrochloride - psikoanaleptiċi - klieb - as an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.